Quarterly ResultAug 12, 2026, 05:02 PM
Atea Pharma Q2 Net Loss $(32.9M); Positive HCV Trial Results
AI Summary
Atea Pharmaceuticals reported a net loss of $(32.9) million for Q2 2026, compared to $(37.2) million in Q2 2025. The company announced positive topline results from its C-BEYOND Phase 3 clinical trial for its HCV treatment, BEM/RZR, demonstrating non-inferiority and potential for a shorter treatment duration. Enrollment for the C-FORWARD trial is complete, with results expected in early Q1 2027, targeting an FDA NDA submission in Q2 2027. The company also initiated a Phase 1 trial for its HEV candidate, AT-587.
Key Highlights
- Q2 2026 net loss was $(32.9) million, compared to $(37.2) million in Q2 2025.
- Net loss per share for Q2 2026 was $(0.41), versus $(0.44) in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $219.5 million as of June 30, 2026.
- Positive topline results from C-BEYOND Phase 3 trial for BEM/RZR (HCV) achieved primary endpoint.
- Completed patient enrollment in C-FORWARD Phase 3 trial for HCV in June 2026.
- Expects C-FORWARD topline results in early Q1 2027, targeting Q2 2027 for NDA submission.
- Initiated Phase 1 clinical trial for AT-587 for the treatment of HEV in July 2026.
- Believes current capital is sufficient to fund operations for at least 12 months.
Price Impact
More from AVIR